MR-guided Focal Laser Ablation of the Prostate

MR-guided Focal Laser Ablation of the Prostate

Purpose of the investigators study is to determine the short and medium term histological cancer control of focal therapy using MR-guided focal laser ablation therapy in the treatment of localised prostate cancer.

Inclusion Criteria:

• Newly diagnosed and biopsy proven prostate cancer
• Intermediate risk patients (PSA <= 20 ng/mL, Gleason ≤ 7, T2b)
• No previous treatment for prostate cancer
• Cancer lesion located at least 1 cm away from the neurovascular bundle according to Multimodality MR images
• Signed informed consent by patient
• Age 18 years or older
• Signed screening form (to determine exclusion for metal device/foreign bodies/claustrophobia)

Exclusion Criteria:

• Impossibility to obtain a valid informed consent
• Patients unable to undergo MR imaging, including those with contra-indications
• Contra-indications to MR guided focal laser therapy (colitis ulcerosa, rectal pathology or abdomino perineal resection)
• Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging
• Patients with evidence for nodal or metastatic disease
• Patients with an estimated Glomerular Filtration Ratio (eGFR) < 40 mL/min/1.73 m2